Expect normal quarter in Q2FY22: Emkay
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
The consortium envisages carrying out surveillance of important bacterial, viral and parasitic infections of zoonotic as well as transboundary pathogens
It works by collecting aerosols and identifies the presence of dangerous pathogens using sensitive, specific and rapid detection in near-real time without laboratory analysis
The survey revealed that improving customer experience (CX) and operational efficiencies are top priorities, which healthcare organizations aim to attain by deploying digital health solutions
Standalone use of Sputnik Light also provides much higher efficacy against severe disease and hospitalizations
This is a virtual event and the theme is `Transforming Healthcare beyond Covid’
The company’s pharmaceutical API products Ibuprofen and fenofibrate got the go-ahead
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
The company plans to raise US $ 15 million
This expansion will support the global operations network and help meet global demand for mammalian development services that support Lonza’s manufacturing sites
Subscribe To Our Newsletter & Stay Updated